Back to Search
Start Over
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
- Source :
- The Lancet; June 2013, Vol. 381 Issue: 9881 p1905-1915, 11p
- Publication Year :
- 2013
-
Abstract
- Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.
Details
- Language :
- English
- ISSN :
- 01406736 and 1474547X
- Volume :
- 381
- Issue :
- 9881
- Database :
- Supplemental Index
- Journal :
- The Lancet
- Publication Type :
- Periodical
- Accession number :
- ejs30509935
- Full Text :
- https://doi.org/10.1016/S0140-6736(13)60023-9